Ignite Creation Date:
2025-12-25 @ 1:39 AM
Ignite Modification Date:
2026-03-01 @ 9:54 PM
Study NCT ID:
NCT01984294
Status:
COMPLETED
Last Update Posted:
2018-11-19
First Post:
2013-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection
Sponsor:
Gilead Sciences
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic HCV Infection | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | HCV genotype 1 | View |
| None | HCV | View |
| None | Sustained Virologic Response | View |
| None | Direct-Acting Antiviral | View |
| None | Combination Therapy | View |
| None | GS-7977 | View |
| None | GS-5885 | View |
| None | Ribavirin | View |
| None | Open Label | View |
| None | Sofosbuvir | View |
| None | Treatment-Naive | View |
| None | Protease Inhibitors | View |
| None | PI | View |
| None | Treatment experienced | View |
| None | Cirrhotic | View |